Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

Retraction Note: Increased survival and cell cycle progression pathways are required for EWS/FLI1-induced malignant transformation.

Javaheri T, Kazemi Z, Pencik J, Pham HTT, Kauer M, Noorizadeh R, Sax B, Nivarthi H, Schlederer M, Maurer B, Hofbauer M, Aryee DNT, Wiedner M, Tomazou EM, Logan M, Hartmann C, Tuckermann JP, Kenner L, Mikula M, Dolznig H, Üren A, Richter GH, Grebien F, Kovar H, Moriggl R.

Cell Death Dis. 2019 Aug 13;10(8):605. doi: 10.1038/s41419-019-1853-1.

2.

STAT3β is a tumor suppressor in acute myeloid leukemia.

Aigner P, Mizutani T, Horvath J, Eder T, Heber S, Lind K, Just V, Moll HP, Yeroslaviz A, Fischer MJM, Kenner L, Győrffy B, Sill H, Grebien F, Moriggl R, Casanova E, Stoiber D.

Blood Adv. 2019 Jul 9;3(13):1989-2002. doi: 10.1182/bloodadvances.2018026385.

3.

High activation of STAT5A drives peripheral T-cell lymphoma and leukemia.

Maurer B, Nivarthi H, Wingelhofer B, Pham HTT, Schlederer M, Suske T, Grausenburger R, Schiefer AI, Prchal-Murphy M, Chen D, Winkler S, Merkel O, Kornauth C, Hofbauer M, Hochgatterer B, Hoermann G, Hoelbl-Kovacic A, Prochazkova J, Lobello C, Cumaraswamy AA, Latzka J, Kitzwögerer M, Chott A, Janikova A, Pospíšilova Š, Loizou JI, Kubicek S, Valent P, Kolbe T, Grebien F, Kenner L, Gunning PT, Kralovics R, Herling M, Müller M, Rülicke T, Sexl V, Moriggl R.

Haematologica. 2019 May 23. pii: haematol.2019.216986. doi: 10.3324/haematol.2019.216986. [Epub ahead of print]

4.

The phosphatase UBASH3B/Sts-1 is a negative regulator of Bcr-Abl kinase activity and leukemogenesis.

Mian AA, Baumann I, Liebermann M, Grebien F, Superti-Furga G, Ruthardt M, Ottmann OG, Hantschel O.

Leukemia. 2019 Sep;33(9):2319-2323. doi: 10.1038/s41375-019-0468-y. Epub 2019 Apr 8. No abstract available.

PMID:
30962580
5.

Dependence on Myb expression is attenuated in myeloid leukaemia with N-terminal CEBPA mutations.

Volpe G, Cauchy P, Walton DS, Ward C, Blakemore D, Bayley R, Clarke ML, Schmidt L, Nerlov C, Garcia P, Dumon S, Grebien F, Frampton J.

Life Sci Alliance. 2019 Mar 15;2(2). pii: e201800207. doi: 10.26508/lsa.201800207. Print 2019 Apr.

6.

Roles of SETD2 in Leukemia-Transcription, DNA-Damage, and Beyond.

Skucha A, Ebner J, Grebien F.

Int J Mol Sci. 2019 Feb 27;20(5). pii: E1029. doi: 10.3390/ijms20051029. Review.

7.

Altered splicing and cytoplasmic levels of tRNA synthetases in SF3B1-mutant myelodysplastic syndromes as a therapeutic vulnerability.

Liberante FG, Lappin K, Barros EM, Vohhodina J, Grebien F, Savage KI, Mills KI.

Sci Rep. 2019 Feb 25;9(1):2678. doi: 10.1038/s41598-019-39591-7.

8.

CEBPA-mutated leukemia is sensitive to genetic and pharmacological targeting of the MLL1 complex.

Schmidt L, Heyes E, Scheiblecker L, Eder T, Volpe G, Frampton J, Nerlov C, Valent P, Grembecka J, Grebien F.

Leukemia. 2019 Jul;33(7):1608-1619. doi: 10.1038/s41375-019-0382-3. Epub 2019 Jan 24.

9.

SETD2 in MLL-rearranged leukemia - a complex case.

Skucha A, Ebner J, Grebien F.

Mol Cell Oncol. 2018 Aug 13;5(4):e1503492. doi: 10.1080/23723556.2018.1503492. eCollection 2018.

10.

Dependency on the TYK2/STAT1/MCL1 axis in anaplastic large cell lymphoma.

Prutsch N, Gurnhofer E, Suske T, Liang HC, Schlederer M, Roos S, Wu LC, Simonitsch-Klupp I, Alvarez-Hernandez A, Kornauth C, Leone DA, Svinka J, Eferl R, Limberger T, Aufinger A, Shirsath N, Wolf P, Hielscher T, Aberger F, Schmoellerl J, Stoiber D, Strobl B, Jäger U, Staber PB, Grebien F, Moriggl R, Müller M, Inghirami GG, Sanda T, Look AT, Turner SD, Kenner L, Merkel O.

Leukemia. 2019 Mar;33(3):696-709. doi: 10.1038/s41375-018-0239-1. Epub 2018 Aug 21.

PMID:
30131584
11.

Correction: Increased survival and cell cycle progression pathways are required for EWS/FLI1-induced malignant transformation.

Javaheri T, Kazemi Z, Jan Pencik, Pham HTT, Kauer M, Noorizadeh R, Sax B, Nivarthi H, Schlederer M, Maurer B, Hofbauer M, Aryee DNT, Wiedner M, Tomazou EM, Logan M, Hartmann C, Tuckermann JP, Kenner L, Mikula M, Dolznig H, Üren A, Richter GH, Grebien F, Kovar H, Moriggl R.

Cell Death Dis. 2018 Jul 23;9(8):800. doi: 10.1038/s41419-018-0773-9.

12.

Oxytocin-like signaling in ants influences metabolic gene expression and locomotor activity.

Liutkevičiūtė Z, Gil-Mansilla E, Eder T, Casillas-Pérez B, Di Giglio MG, Muratspahić E, Grebien F, Rattei T, Muttenthaler M, Cremer S, Gruber CW.

FASEB J. 2018 Jun 25:fj201800443. doi: 10.1096/fj.201800443. [Epub ahead of print]

13.

MLL-fusion-driven leukemia requires SETD2 to safeguard genomic integrity.

Skucha A, Ebner J, Schmöllerl J, Roth M, Eder T, César-Razquin A, Stukalov A, Vittori S, Muhar M, Lu B, Aichinger M, Jude J, Müller AC, Győrffy B, Vakoc CR, Valent P, Bennett KL, Zuber J, Superti-Furga G, Grebien F.

Nat Commun. 2018 May 18;9(1):1983. doi: 10.1038/s41467-018-04329-y.

14.

Pharmacologic inhibition of STAT5 in acute myeloid leukemia.

Wingelhofer B, Maurer B, Heyes EC, Cumaraswamy AA, Berger-Becvar A, de Araujo ED, Orlova A, Freund P, Ruge F, Park J, Tin G, Ahmar S, Lardeau CH, Sadovnik I, Bajusz D, Keserű GM, Grebien F, Kubicek S, Valent P, Gunning PT, Moriggl R.

Leukemia. 2018 May;32(5):1135-1146. doi: 10.1038/s41375-017-0005-9. Epub 2018 Feb 2.

15.

STAT5BN642H is a driver mutation for T cell neoplasia.

Pham HTT, Maurer B, Prchal-Murphy M, Grausenburger R, Grundschober E, Javaheri T, Nivarthi H, Boersma A, Kolbe T, Elabd M, Halbritter F, Pencik J, Kazemi Z, Grebien F, Hengstschläger M, Kenner L, Kubicek S, Farlik M, Bock C, Valent P, Müller M, Rülicke T, Sexl V, Moriggl R.

J Clin Invest. 2018 Jan 2;128(1):387-401. doi: 10.1172/JCI94509. Epub 2017 Dec 4.

16.

Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target site.

Hadzijusufovic E, Albrecht-Schgoer K, Huber K, Hoermann G, Grebien F, Eisenwort G, Schgoer W, Herndlhofer S, Kaun C, Theurl M, Sperr WR, Rix U, Sadovnik I, Jilma B, Schernthaner GH, Wojta J, Wolf D, Superti-Furga G, Kirchmair R, Valent P.

Leukemia. 2017 Nov;31(11):2388-2397. doi: 10.1038/leu.2017.245. Epub 2017 Jul 31.

17.

Analysis of the interplay between all-trans retinoic acid and histone deacetylase inhibitors in leukemic cells.

Noack K, Mahendrarajah N, Hennig D, Schmidt L, Grebien F, Hildebrand D, Christmann M, Kaina B, Sellmer A, Mahboobi S, Kubatzky K, Heinzel T, Krämer OH.

Arch Toxicol. 2017 May;91(5):2191-2208. doi: 10.1007/s00204-016-1878-5. Epub 2016 Nov 2.

18.

Increased survival and cell cycle progression pathways are required for EWS/FLI1-induced malignant transformation.

Javaheri T, Kazemi Z, Pencik J, Pham HT, Kauer M, Noorizadeh R, Sax B, Nivarthi H, Schlederer M, Maurer B, Hofbauer M, Aryee DN, Wiedner M, Tomazou EM, Logan M, Hartmann C, Tuckermann JP, Kenner L, Mikula M, Dolznig H, Üren A, Richter GH, Grebien F, Kovar H, Moriggl R.

Cell Death Dis. 2016 Oct 13;7(10):e2419. doi: 10.1038/cddis.2016.268. Erratum in: Cell Death Dis. 2018 Jul 23;9(8):800. Retraction in: Cell Death Dis. 2019 Aug 13;10(8):605.

19.

NVT: a fast and simple tool for the assessment of RNA-seq normalization strategies.

Eder T, Grebien F, Rattei T.

Bioinformatics. 2016 Dec 1;32(23):3682-3684. doi: 10.1093/bioinformatics/btw521. Epub 2016 Aug 11.

20.

JAK-STAT signaling in cancer: From cytokines to non-coding genome.

Pencik J, Pham HT, Schmoellerl J, Javaheri T, Schlederer M, Culig Z, Merkel O, Moriggl R, Grebien F, Kenner L.

Cytokine. 2016 Nov;87:26-36. doi: 10.1016/j.cyto.2016.06.017. Epub 2016 Jun 24. Review.

21.

Erratum: STAT3 regulated ARF expression suppresses prostate cancer metastasis.

Pencik J, Schlederer M, Gruber W, Unger C, Walker SM, Chalaris A, Marié IJ, Hassler MR, Javaheri T, Aksoy O, Blayney JK, Prutsch N, Skucha A, Herac M, Krämer OH, Mazal P, Grebien F, Egger G, Poli V, Mikulits W, Eferl R, Esterbauer H, Kennedy R, Fend F, Scharpf M, Braun M, Perner S, Levy DE, Malcolm T, Turner SD, Haitel A, Susani M, Moazzami A, Rose-John S, Aberger F, Merkel O, Moriggl R, Culig Z, Dolznig H, Kenner L.

Nat Commun. 2015 Oct 26;6:8802. doi: 10.1038/ncomms9802. No abstract available.

PMID:
26499136
22.

Erratum: Pharmacological targeting of the Wdr5-MLL interaction in C/EBPα N-terminal leukemia.

Grebien F, Vedadi M, Getlik M, Giambruno R, Grover A, Avellino R, Skucha A, Vittori S, Kuznetsova E, Smil D, Barsyte-Lovejoy D, Li F, Poda G, Schapira M, Wu H, Dong A, Senisterra G, Stukalov A, Huber KV, Schönegger A, Marcellus R, Bilban M, Bock C, Brown PJ, Zuber J, Bennett KL, Al-Awar R, Delwel R, Nerlov C, Arrowsmith CH, Superti-Furga G.

Nat Chem Biol. 2015 Oct;11(10):815. doi: 10.1038/nchembio1015-815b. No abstract available.

PMID:
26379026
23.

STAT3 regulated ARF expression suppresses prostate cancer metastasis.

Pencik J, Schlederer M, Gruber W, Unger C, Walker SM, Chalaris A, Marié IJ, Hassler MR, Javaheri T, Aksoy O, Blayney JK, Prutsch N, Skucha A, Herac M, Krämer OH, Mazal P, Grebien F, Egger G, Poli V, Mikulits W, Eferl R, Esterbauer H, Kennedy R, Fend F, Scharpf M, Braun M, Perner S, Levy DE, Malcolm T, Turner SD, Haitel A, Susani M, Moazzami A, Rose-John S, Aberger F, Merkel O, Moriggl R, Culig Z, Dolznig H, Kenner L.

Nat Commun. 2015 Jul 22;6:7736. doi: 10.1038/ncomms8736. Erratum in: Nat Commun. 2015;6:8802.

24.

Pharmacological targeting of the Wdr5-MLL interaction in C/EBPα N-terminal leukemia.

Grebien F, Vedadi M, Getlik M, Giambruno R, Grover A, Avellino R, Skucha A, Vittori S, Kuznetsova E, Smil D, Barsyte-Lovejoy D, Li F, Poda G, Schapira M, Wu H, Dong A, Senisterra G, Stukalov A, Huber KVM, Schönegger A, Marcellus R, Bilban M, Bock C, Brown PJ, Zuber J, Bennett KL, Al-Awar R, Delwel R, Nerlov C, Arrowsmith CH, Superti-Furga G.

Nat Chem Biol. 2015 Aug;11(8):571-578. doi: 10.1038/nchembio.1859. Epub 2015 Jul 13. Erratum in: Nat Chem Biol. 2015 Oct;11(10):815.

25.

Acceleration of Bcr-Abl+ leukemia induced by deletion of JAK2.

Grundschober E, Hoelbl-Kovacic A, Bhagwat N, Kovacic B, Scheicher R, Eckelhart E, Kollmann K, Keller M, Grebien F, Wagner KU, Levine RL, Sexl V.

Leukemia. 2014 Sep;28(9):1918-22. doi: 10.1038/leu.2014.152. Epub 2014 May 5. No abstract available.

26.

Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanisms.

Li J, Bennett K, Stukalov A, Fang B, Zhang G, Yoshida T, Okamoto I, Kim JY, Song L, Bai Y, Qian X, Rawal B, Schell M, Grebien F, Winter G, Rix U, Eschrich S, Colinge J, Koomen J, Superti-Furga G, Haura EB.

Mol Syst Biol. 2013 Nov 5;9:705. doi: 10.1038/msb.2013.61.

27.

Affinity purification strategies for proteomic analysis of transcription factor complexes.

Giambruno R, Grebien F, Stukalov A, Knoll C, Planyavsky M, Rudashevskaya EL, Colinge J, Superti-Furga G, Bennett KL.

J Proteome Res. 2013 Sep 6;12(9):4018-27. doi: 10.1021/pr4003323. Epub 2013 Aug 22.

28.

Systems-pharmacology dissection of a drug synergy in imatinib-resistant CML.

Winter GE, Rix U, Carlson SM, Gleixner KV, Grebien F, Gridling M, Müller AC, Breitwieser FP, Bilban M, Colinge J, Valent P, Bennett KL, White FM, Superti-Furga G.

Nat Chem Biol. 2012 Nov;8(11):905-912. doi: 10.1038/nchembio.1085. Epub 2012 Sep 30.

29.

The growing arsenal of ATP-competitive and allosteric inhibitors of BCR-ABL.

Hantschel O, Grebien F, Superti-Furga G.

Cancer Res. 2012 Oct 1;72(19):4890-5. doi: 10.1158/0008-5472.CAN-12-1276. Epub 2012 Sep 21. Review.

30.

Optimisation of Downscaled Tandem Affinity Purifications to Identify Core Protein Complexes.

Haura EB, Sacco R, Li J, Müller AC, Grebien F, Superti-Furga G, Bennett KL.

J Integr OMICS. 2012 May;2(1):55-68.

31.

BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia.

Hantschel O, Warsch W, Eckelhart E, Kaupe I, Grebien F, Wagner KU, Superti-Furga G, Sexl V.

Nat Chem Biol. 2012 Jan 29;8(3):285-93. doi: 10.1038/nchembio.775.

PMID:
22286129
32.

Targeting allosteric regulatory modules in oncoproteins: "drugging the undruggable".

Hantschel O, Grebien F, Superti-Furga G.

Oncotarget. 2011 Nov;2(11):828-9. No abstract available.

33.

Targeting the SH2-kinase interface in Bcr-Abl inhibits leukemogenesis.

Grebien F, Hantschel O, Wojcik J, Kaupe I, Kovacic B, Wyrzucki AM, Gish GD, Cerny-Reiterer S, Koide A, Beug H, Pawson T, Valent P, Koide S, Superti-Furga G.

Cell. 2011 Oct 14;147(2):306-19. doi: 10.1016/j.cell.2011.08.046.

34.

CD14 is a coreceptor of Toll-like receptors 7 and 9.

Baumann CL, Aspalter IM, Sharif O, Pichlmair A, Blüml S, Grebien F, Bruckner M, Pasierbek P, Aumayr K, Planyavsky M, Bennett KL, Colinge J, Knapp S, Superti-Furga G.

J Exp Med. 2010 Nov 22;207(12):2689-701. doi: 10.1084/jem.20101111. Epub 2010 Nov 15.

35.

Using iTRAQ combined with tandem affinity purification to enhance low-abundance proteins associated with somatically mutated EGFR core complexes in lung cancer.

Haura EB, Müller A, Breitwieser FP, Li J, Grebien F, Colinge J, Bennett KL.

J Proteome Res. 2011 Jan 7;10(1):182-90. doi: 10.1021/pr100863f. Epub 2010 Nov 9.

36.

A potent and highly specific FN3 monobody inhibitor of the Abl SH2 domain.

Wojcik J, Hantschel O, Grebien F, Kaupe I, Bennett KL, Barkinge J, Jones RB, Koide A, Superti-Furga G, Koide S.

Nat Struct Mol Biol. 2010 Apr;17(4):519-27. doi: 10.1038/nsmb.1793. Epub 2010 Mar 28.

37.

Stat5 is indispensable for the maintenance of bcr/abl-positive leukaemia.

Hoelbl A, Schuster C, Kovacic B, Zhu B, Wickre M, Hoelzl MA, Fajmann S, Grebien F, Warsch W, Stengl G, Hennighausen L, Poli V, Beug H, Moriggl R, Sexl V.

EMBO Mol Med. 2010 Mar;2(3):98-110. doi: 10.1002/emmm.201000062.

38.

Structural coupling of SH2-kinase domains links Fes and Abl substrate recognition and kinase activation.

Filippakopoulos P, Kofler M, Hantschel O, Gish GD, Grebien F, Salah E, Neudecker P, Kay LE, Turk BE, Superti-Furga G, Pawson T, Knapp S.

Cell. 2008 Sep 5;134(5):793-803. doi: 10.1016/j.cell.2008.07.047.

39.

Stat5 regulates cellular iron uptake of erythroid cells via IRP-2 and TfR-1.

Kerenyi MA, Grebien F, Gehart H, Schifrer M, Artaker M, Kovacic B, Beug H, Moriggl R, Müllner EW.

Blood. 2008 Nov 1;112(9):3878-88. doi: 10.1182/blood-2008-02-138339. Epub 2008 Aug 11.

40.

The different functions of Stat5 and chromatin alteration through Stat5 proteins.

Kornfeld JW, Grebien F, Kerenyi MA, Friedbichler K, Kovacic B, Zankl B, Hoelbl A, Nivarti H, Beug H, Sexl V, Muller M, Kenner L, Mullner EW, Gouilleux F, Moriggl R.

Front Biosci. 2008 May 1;13:6237-54. Review.

41.

Stat5 activation enables erythropoiesis in the absence of EpoR and Jak2.

Grebien F, Kerenyi MA, Kovacic B, Kolbe T, Becker V, Dolznig H, Pfeffer K, Klingmüller U, Müller M, Beug H, Müllner EW, Moriggl R.

Blood. 2008 May 1;111(9):4511-22. doi: 10.1182/blood-2007-07-102848. Epub 2008 Jan 31.

42.

Erythroid progenitor renewal versus differentiation: genetic evidence for cell autonomous, essential functions of EpoR, Stat5 and the GR.

Dolznig H, Grebien F, Deiner EM, Stangl K, Kolbus A, Habermann B, Kerenyi MA, Kieslinger M, Moriggl R, Beug H, Müllner EW.

Oncogene. 2006 May 11;25(20):2890-900.

43.

Cell size control: new evidence for a general mechanism.

Grebien F, Dolznig H, Beug H, Mullner EW.

Cell Cycle. 2005 Mar;4(3):418-21. Epub 2005 Mar 4. Review.

PMID:
15703475
44.

Evidence for a size-sensing mechanism in animal cells.

Dolznig H, Grebien F, Sauer T, Beug H, Müllner EW.

Nat Cell Biol. 2004 Sep;6(9):899-905. Epub 2004 Aug 22.

PMID:
15322555

Supplemental Content

Loading ...
Support Center